Rafferty Asset Management LLC Sells 13,522 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)

Rafferty Asset Management LLC decreased its stake in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 20.6% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 52,168 shares of the company's stock after selling 13,522 shares during the period. Rafferty Asset Management LLC owned 0.10% of Janux Therapeutics worth $2,793,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of JANX. Barclays PLC boosted its holdings in Janux Therapeutics by 496.5% in the 3rd quarter. Barclays PLC now owns 174,061 shares of the company's stock valued at $7,907,000 after purchasing an additional 144,883 shares during the period. Franklin Resources Inc. boosted its holdings in Janux Therapeutics by 64.5% in the 3rd quarter. Franklin Resources Inc. now owns 18,983 shares of the company's stock valued at $937,000 after purchasing an additional 7,442 shares during the period. Avanza Fonder AB bought a new stake in Janux Therapeutics in the 4th quarter valued at about $139,000. China Universal Asset Management Co. Ltd. boosted its holdings in Janux Therapeutics by 10.9% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,128 shares of the company's stock valued at $596,000 after purchasing an additional 1,095 shares during the period. Finally, Chicago Capital LLC bought a new stake in Janux Therapeutics in the 4th quarter valued at about $230,000. Institutional investors own 75.39% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on JANX. HC Wainwright restated a "buy" rating and issued a $70.00 target price on shares of Janux Therapeutics in a research report on Monday, March 3rd. Scotiabank dropped their target price on shares of Janux Therapeutics from $62.00 to $41.00 and set a "sector perform" rating for the company in a research report on Friday, February 28th. Finally, Wedbush restated an "outperform" rating and issued a $76.00 target price (up from $75.00) on shares of Janux Therapeutics in a research report on Friday, February 28th. One analyst has rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $95.25.

Janux Therapeutics Trading Down 0.5%

JANX stock opened at $24.17 on Tuesday. The firm has a 50 day moving average of $28.50 and a 200-day moving average of $40.33. Janux Therapeutics, Inc. has a 12 month low of $22.48 and a 12 month high of $71.71. The firm has a market capitalization of $1.43 billion, a P/E ratio of -20.66 and a beta of 3.24.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.43) by $0.05. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. Sell-side analysts predict that Janux Therapeutics, Inc. will post -1.38 EPS for the current year.

Insiders Place Their Bets

In other Janux Therapeutics news, Director Ra Capital Management, L.P. bought 341,742 shares of Janux Therapeutics stock in a transaction dated Wednesday, March 5th. The shares were purchased at an average cost of $30.64 per share, with a total value of $10,470,974.88. Following the transaction, the director now directly owns 9,658,988 shares of the company's stock, valued at $295,951,392.32. This represents a 3.67% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Andrew Hollman Meyer sold 3,333 shares of the stock in a transaction dated Thursday, May 1st. The shares were sold at an average price of $32.03, for a total transaction of $106,755.99. Following the sale, the insider now directly owns 82,139 shares in the company, valued at $2,630,912.17. This trade represents a 3.90% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 10,001 shares of company stock valued at $313,964. 8.10% of the stock is currently owned by corporate insiders.

Janux Therapeutics Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.

Want to see what other hedge funds are holding JANX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.